Encorafenib clinical trials
Also written LGX818, Braftovi and ONO-7702.
How each study uses encorafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the encorafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Jun 2018 · BRAFTOVI · NDA 210496 (FDA, Drugs@FDA)
- European Union
- 19 Sept 2018 · Braftovi · EMEA/H/C/004580 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
60 studies that test it; most in 2021 (9)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 4 |
| 2018 | 4 |
| 2019 | 8 |
| 2020 | 8 |
| 2021 | 9 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 26 · Other 34
Pfizer (17) · Pierre Fabre Medicament (5) · M.D. Anderson Cancer Center (4) · Array BioPharma (3) · Memorial Sloan Kettering Cancer Center (2) · Peter MacCallum Cancer Centre, Australia (2) · Intergroupe Francophone de Cancerologie Thoracique (1) · Alliance for Clinical Trials in Oncology (1)
Often tested with
Tested in the same studies.
Binimetinib (38) · Cetuximab (13) · Nivolumab (8) · Ribociclib (5) · Pembrolizumab (4) · Dabrafenib (3) · Trametinib (3) · Palbociclib (3)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8, 2 in phase 3
Studies that test encorafenib, phase 3 first.
- Mar 2027Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Phase 3 · Pierre Fabre Medicament
- Jun 2027Personalized Medicine for Advanced Biliary Cancer PatientsPhase 3 · UNICANCER
- Dec 2026Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF MutationsPhase 2 · University Health Network, Toronto
- Dec 2026Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum CancerPhase 2 · Federation Francophone de Cancerologie Digestive
- Feb 2027Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesPhase 2 · M.D. Anderson Cancer Center
- May 2027Combination Therapy for BRAF-V600E Metastatic CRCmPhase 2 · Vall d'Hebron Institute of Oncology
- Jun 2027A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesPhase 2 · SWOG Cancer Research Network
- Nov 2027ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerEarly Phase 1 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses encorafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 60
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Encorafenib
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Encorafenib
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingPhase 2SWOG Cancer Research NetworkNCT04511013Written as Encorafenib
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Encorafenib
- Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05026983Written as Encorafenib
- Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum CancerRecruitingPhase 2Federation Francophone de Cancerologie DigestiveNCT05706779Written as Encorafenib Oral Capsule + Cetuximab
- Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.RecruitingPhase 2Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06640166Written as encorafenib + cetuximab + FOLFIRI
- Combination Therapy for BRAF-V600E Metastatic CRCmRecruitingPhase 2Vall d'Hebron Institute of OncologyNCT06411600Written as Encorafenib
- Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATERecruitingPhase 1/2Peter MacCallum Cancer Centre, AustraliaNCT04720768Written as Encorafenib
- Melanoma Metastasized to the Brain and SteroidsRecruitingPhase 2Inge Marie SvaneNCT03563729Written as Encorafenib
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200Written as Encorafenib
- Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04017650Written as Encorafenib
- A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingPhase 3PfizerNCT04607421Written as Encorafenib
- Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRCCompletedPhase 2Gruppo Oncologico del Nord-OvestNCT06578559Written as Encorafenib
- Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementTerminatedPhase 2ECOG-ACRIN Cancer Research GroupNCT04221438Written as Encorafenib
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaActive, not recruitingPhase 3PfizerNCT04657991Written as Encorafenib
- ENCOrafenib With Binimetinib in bRAF NSCLCActive, not recruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT04526782Written as Encorafenib 75 MG
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingPhase 2PfizerNCT05217446Written as Encorafenib
- Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerCompletedPhase 2Pierre Fabre MedicamentNCT03693170Written as encorafenib
- Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon CancerActive, not recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT05710406Written as Encorafenib
See all 60 studies that test encorafenib →
Given beside what is tested · 11 — encorafenib is usual care or a partner of the new treatment
- Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06102902Written as Encorafenib
- Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyRecruitingPhase 1M.D. Anderson Cancer CenterNCT05985954Written as Encorafenib
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingPhase 1Rina PlattnerNCT04903119Written as Encorafenib
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingPhase 1/2University of UtahNCT06194929Written as Encorafenib
- Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05308446Written as Encorafenib
- Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisActive, not recruitingPhase 2UNICANCERNCT04074096Written as Encorafenib Oral Capsule
- PF-07284892 in Participants With Advanced Solid TumorsTerminatedPhase 1PfizerNCT04800822Written as encorafenib
- A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesCompletedPhase 1/2Erasca, Inc.NCT05039177Written as Encorafenib
- ZN-c3 in Adult Participants With Metastatic Colorectal CancerTerminatedPhase 1K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05743036Written as Encorafenib
- A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerCompletedPhase 1Eli Lilly and CompanyNCT02857270Written as Encorafenib
- CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Status unknownPhase 1Curegenix Inc.NCT02675946Written as encorafenib
Codes
What other systems call encorafenib · ClinicalTrials.gg INT000307
- MeSH (NLM) C000601108encorafenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8L7891MRB6ENCORAFENIBConfirmed FDA, NLM, Wikidata
- RxNorm 2049106Confirmed FDA, Wikidata
- Wikidata Q15409405encorafenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98283EncorafenibOne source FDA
- DrugBank DB11718One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601108 | encorafenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8L7891MRB6 | ENCORAFENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2049106 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15409405 | encorafenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98283 | Encorafenib | One source FDA |
| DrugBank | DB11718 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.